Tissue homeostasis requires tight regulation of cellular proliferation, differentiation and apoptosis. E2F1 and E2F2 transcription factors share a critical role in tissue homeostasis, since their combined inactivation results in overall organ involution, specially affecting the pancreatic gland, which subsequently triggers diabetes. We have examined the mechanism by which these E2Fs regulate tissue homeostasis. We show that pancreas atrophy in E2F1/E2F2 double-knockout (DKO) mice is associated with mitochondrial apoptosis and activation of the p53 pathway in young animals, before the development of diabetes. A deregulated expression of E2F target genes was detected in pancreatic cells of young DKO animals, along with unscheduled DNA replication and activation of a DNA damage response. Importantly, suppression of DNA replication in vivo with aphidicolin led to a significant inhibition of the p53 pathway in DKO pancreas, implying a causal link between DNA replication stress and p53 activation in this model. We further show that activation of the p53 pathway has a key role in the aberrant phenotype of DKO mice, since targeted inactivation of p53 gene abrogated cellular apoptosis and prevented organ involution and insulin-dependent diabetes in mice lacking E2F1/E2F2. Unexpectedly, p53 inactivation unmasked oncogenic features of E2F1/E2F2-depleted cells, as evidenced by an accelerated tumor development in triple-knockout mice compared with p53 − / − mice. Collectively, our data reveal a role for E2F1 and E2F2 as suppressors of replicative stress in differentiating cells, and uncover the existence of a robust E2F-p53 regulatory axis to enable tissue homeostasis and prevent tumorigenesis. These findings have implications in the design of approaches targeting E2F for cancer therapy.
The challenges that cells face to maintain a differentiated status within a tissue entail overcoming a number of obstacles, such as uncontrolled proliferation, damaged organelles, ROS or DNA breaks. Aberrant cells can activate surveillance pathways to be eliminated, or they may, alternatively, accumulate. Lack of balance between these two decisions results in tissue degeneration or in tumorigenesis. Cancer cells commonly exhibit deregulation of a functional pRb pathway. 1 Such deregulation can occur at multiple points of the pathway, including mutations or deletions of pRb gene itself, activation of cyclin/CDKs that phosphorylate and thereby functionally inactivate pRb, or inactivation of CDK inhibitors, such as p16 INK4A . 2 The oncogenic stress induced by loss of pRb function is known to activate the other major tumor suppressor, p53.
2 Activated p53 can, depending on the cellular context, induce cell-cycle arrest, senescence or apoptosis as a failsafe mechanism against tumorigenesis, and the combined loss of pRb and p53 pathways leave cells prone to tumorigenesis. Conversely, hiperactivation of the p53 pathway upon oncogenic stress induced by pRb loss prevents tumor development, yet premature aging may arise leading to a reduction in lifespan. 3 An extensively characterized function of pRb involves its interaction with members of the E2F family of transcription factors, whereby hypophosphorylated pRb protein forms a complex with E2F members and blocks their transcriptional activity, preventing entry into the cell cycle. 4 Cyclin/CDKmediated phosphorylation of pRb during G1 releases E2F, thus allowing gene transcription and cell-cycle progression. Inactivation of the pRb pathway is thought to lead to inappropriate activation of E2F factors, followed by increased cellular proliferation rates and tumorigenesis. 5 Thus, inhibition of E2F activity has been proposed as a therapeutic strategy for the treatment of cancer. 6 Mammalian E2F comprises a family of eight transcription factors, originally discovered for their crucial role in the control of cell-cycle progression through the regulation of a large set of responsive genes. [7] [8] [9] Subsequently, it was shown that E2Fs also have essential roles in a wide range of functions such as differentiation, apoptosis and DNA repair, underlying their relevance in tissue homeostasis. [8] [9] [10] E2F1 and E2F2 are known to function both as transcriptional activators and as repressors of their target genes, including those coding for microRNAs. [11] [12] [13] [14] [15] Moreover, E2F1
and E2F2 perform positive as well as negative regulatory roles in cellular proliferation, which appear to be cell specific and context dependent. They have been reported to promote cellcycle entry and progression upon their ectopic expression. 16 By contrast, targeted inactivation of these E2Fs revealed their essential role in sustaining quiescence in hematopoietic cells, 11 in supporting survival of progenitor cells 16 or in facilitating exit from the cell cycle in differentiating cells. 13, 17 However, the mechanisms by which E2F1 and E2F2 accomplish such diverse functions remain unresolved.
The pancreas has emerged as an optimal system to unravel the role of E2F1 and E2F2 in the maintenance of tissue homeostasis. We and others have previously reported that combined inactivation of E2F1 and E2F2 transcription factors leads to exocrine and endocrine pancreatic dysfunction, causing diabetes and the collapse of the entire pancreas. 18, 19 After a period of strong cell division cycles, which take place during embryonic development and finalize by the second week after birth, pancreatic tissue is virtually post-mitotic. 20 By contrast, pancreatic cells lacking E2F1 and E2F2 continue cycling aberrantly well beyond this age. 19 Strikingly, E2F1/E2F2 mutant pancreas exhibits an increased apoptotic rate and the organ degenerates rapidly. 19 Other organs in E2F1/E2F2 DKO mice also show a singular involution, particularly the hematopoietic system, salivary glands and testicles, 19 although the mediators involved in E2F1/E2F2-dependent tissue atrophy have not yet been identified.
Here, we explore the mechanism by which E2F1 and E2F2 regulate tissue homeostasis. We show that inactivation of E2F1 and E2F2 results in accumulation of DNA replication mediators, activation of the DNA damage response (DDR) and induction of p53-dependent apoptosis. Genetic elimination of p53 abrogates apoptosis and pancreatic gland involution, and rescues insulin-dependent diabetes. Importantly, the absence of p53 also uncovers oncogenic features of E2F1/E2F2-depleted cells. Collectively, our data stress the relevance of E2F1 and E2F2 as suppressors of replicative stress and regulators of cell-cycle exit during differentiation, and reveal the existence of a robust E2F-p53 regulatory axis to ensure proper organ function and prevent tumorigenesis.
Results
Apoptosis in pancreas lacking E2F1 and E2F2 is associated with p53 accumulation. E2F1/E2F2 doubleknockout (DKO) pancreatic cells exhibit increased rates of apoptosis as early as postnatal day 15, before manifestations of pancreatic atrophy. 19 To characterize the apoptotic cell death, we isolated pancreatic cells from 2-week-old DKO and wild-type mice and measured changes in mitochondrial membrane potential by examining fluorescence of cells incubated with JC-1 ( Figure 1a) . In live cells, JC-1 monomers form aggregates and emit both green and red fluorescence, while in dying cells with collapsed Δψ m , JC-1 is only monomeric and emits exclusively green fluorescence. The percentage of cells positive for green fluorescence and negative for red fluorescence was substantially higher in DKO samples compared with wild-type controls (45.46 ± 7.06% versus 15.51 ± 1.07%), suggesting mitochondrial apoptosis. Consistent with this result, we detected a reduction of mitochondrial mass in DKO pancreatic cells, as evidenced by the marked difference in fluorescence intensity between DKO and wild-type samples treated with the cardiolipinbinding molecule Nonyl-Acrydine-Orange (NAO) (Figure 1b) . To get an insight into the underlying mechanism of apoptosis, we examined p53 protein expression. Accumulation of p53 was detected in the pancreas of DKO mice (Figure 1c) . Furthermore, typical p53 direct transcriptional target genes involved in intrinsic (Bax, Puma, Apaf-1, Pidd) and extrinsic (Dr5) pathways were significantly overexpressed in DKO samples (Figure 1d ). Taken together, these results suggest that E2F1/E2F2 double-deficient pancreatic cells undergo apoptosis as a result of p53 protein accumulation and activation.
The levels of p53 can be increased in cells by diverse mechanisms, some of which are mediated by E2F target genes, including p19 ARF , Sirt1 and Sirt3. 21, 22 To assess their role in p53 accumulation in our model, we analyzed the expression of these genes in E2F1/E2F2-depleted cells. The expression of p19 ARF was reduced in DKO pancreas, at both the mRNA and protein levels (Figures 1e and f) . Additionally, Sirt1 and Sirt3 mRNA levels remained unchanged in DKO samples compared with WT controls (Figure 1e ), and no p53 hyperacetylation was observed (Figure 1f ). These results rule out a role for p19 ARF and Sirt proteins in the accumulation of p53 displayed by DKO pancreases.
We also examined levels of reactive oxygen species (ROS), which are known to activate p53 via Apex1. 23 However, ROS or Apex1 protein accumulation was not detected in young DKO mice (Figures 1f and g ), and only older diabetic DKO mice showed elevated ROS accumulation (Figure 1g ), indicating that activation of p53 pathway in DKO pancreas is not ROS dependent.
Deregulated E2F target gene expression and aberrant cell-cycle control in pancreas of mice deficient in E2F1 and E2F2. To further characterize the phenotype observed in E2F1/E2F2-depleted pancreatic cells, we analyzed DNA synthesis in pancreas of 2-week-old mice. By this age, wild-type pancreas is virtually post-mitotic. As expected, DNA synthesis was essentially undetectable in WT controls (Figure 2a ). In contrast, unscheduled DNA replication was detected in E2F1/E2F2 DKO cells. Consistent with these results, we detected an upregulated expression of E2F target genes that promote DNA synthesis and positively regulate G1/S transition and mitosis (Figure 2b) .
We also examined the expression of E2F targets that encode CDK regulators. The levels of p16 INK4A and p27
KIP1
were unchanged in DKO cells relative to WT samples. By contrast, the expression of p21 CIP1 and Cdc25a was increased in DKO cells and the expression of the G1 CDKi p18
INK4C was significantly reduced (Figure 2b ).
Elevated levels of phosphorylated pRb (Ser807/811 and Ser780) were detected in DKO pancreatic cells, suggesting hyperactivation of G1 cyclin/CDK function. Similarly, mitotic cyclin/CDK activity appeared significantly elevated in DKO cells, as evidenced by the near disappearance of the Cdk1 inhibitory Tyr15 phosphorylation, the increased levels of cyclin E2F-p53 regulatory axis in tissue homeostasis A Iglesias-Ara et al B1 and Cdc25c, and the nearly complete absence of Wee1 protein ( Figure 2c ). An increased Cdk1 activity is consistent with the accumulation of the mitotic marker phospho-histone H3 (pH3) that was noted in DKO pancreas ( Figure 2a ). Taken together, these findings suggest that terminally differentiating DKO pancreatic cells are progressing aberrantly through the cell cycle in the absence of repressive signals emanated from E2F1 and E2F2 to promote cell-cycle exit.
p53 accumulation in the pancreas of DKO mice is linked to DNA replication stress. Given the aberrant cyclin/ CDK activity observed in DKO samples, we examined DNA damage response (DDR) in pancreas by assessing accumulation of γ-H2AX, a marker for DNA breaks. Western blotting of pancreatic lysates from 7-day-old mice did not show global accumulation of γ-H2AX. However, the levels of γ-H2AX increased significantly in 15-day-old DKO mice and were dramatically higher in adult mice ( Figure 3a ). Immunohistochemical analysis evidenced that over 6% of pancreatic cells were positive for γ-H2AX in 15-day-old DKO mice (Figure 3b) . Importantly, γ-H2AX positivity was not observed in organs that undergo scheduled DNA replication, such as the small intestine. Intestinal crypt cells from small intestine exhibited actively replicating DNA in both WT and DKO mice, but no γ-H2AX-positive cells were detected in either genotype (Supplementary Figure1A ). Taken together, our results suggest that the unscheduled DNA replication observed in pancreatic cells lacking E2F1/E2F2 may lead to a strong DDR.
To examine the relationship between DNA replication stress and DDR in E2F1/E2F2 mutant pancreas, we treated DKO and WT mice (15-20 days old) with the DNA polymerase inhibitor aphidicolin to inhibit DNA replication in vivo. 24 As a control, we showed that in vivo administration of aphidicolin was able to reduce DNA replication substantially in the small intestine of both WT and DKO mice (Supplementary Figure 1B) . In the pancreas of DKO mice in vivo aphidicolin treatment blocked DNA replication, as evidenced by the reduction in bromodeoxyuridine (BrdU) uptake (Figure 3c , left panels). Next, we examined the expression of γ-H2AX by immunohistochemistry. Importantly, aphidicolin reduced the number of cells with γ-H2AX staining in DKO pancreas (Figure 3c , right panels). Furthermore, western analyses showed that inhibition of DNA replication by aphidicolin prevented the accumulation of p53 and p21 CIP1 in a dosedependent manner in DKO pancreas (Figure 3d) . We conclude that the abnormal DNA replication and the resulting replication stress trigger DDR and subsequent activation of p53 pathway in DKO pancreas.
p21
CIP1 is dispensable for the aberrant pancreatic phenotype developed by cells lacking E2F1/E2F2. We next analyzed the contribution of the pathways governed by p53 and its transcriptional target p21 CIP1 to the atrophy of DKO pancreas. We first generated E2F1/E2F2/p21 CIP1 triple-knockout (TKO) mice and examined these mice in parallel with E2F1
− / − and wild-type mice. Loss of p21 CIP1 did not reverse the histological abnormalities previously described in adult DKO pancreases. In fact, these abnormalities were more severe in E2F1/E2F2/p21 CIP1 TKO mice (Supplementary Figure 2) . Consistently, loss of p21 CIP1 did not prevent the overexpression of apoptosis markers, the pancreatic atrophy or the hyperglycemia in E2F1/E2F2 DKO mice (Supplementary Figure 3) . Other organs that exhibit involution in DKO mice, such as salivary glands, testicles and hematopoietic system, remained atrophic in the TKO animals (data not shown). These findings suggest that the mechanism that dictates cell death induction and triggers organ involution in E2F1/E2F2 DKO mice is p21 CIP1 independent.
Disruption of p53 in E2F1/E2F2-deficient mice prevents apoptosis and restores a normal pancreatic phenotype. We next generated E2F1/E2F2/p53 TKO mice and analyzed these mice in parallel with E2F1
− / − /E2F2 − / − , p53 − / − and wild-type mice. Importantly, the expression of p53 target genes (Bax, Puma, Apaf-1, Pidd and Dr5) was down to normal in E2F1/E2F2/p53 TKO pancreases compared with (Figure 4a ). Consistent with this result, compromised mitochondrial membrane potential was completely rescued in pancreatic cells isolated from TKO animals (Figure 4b ), and elimination of p53 from E2F1/E2F2 DKO cells restored cell survival (Figure 4c ). By contrast, increased BrdU uptake and accumulation of γ-H2AX persisted in E2F1/E2F2/p53 TKO cells (Supplementary  Figure 4) . These findings place p53 downstream of DNA replication stress signals and upstream of apoptotic pathways after E2F1/2 loss. Strikingly, elimination of p53 completely prevented loss of insulin-and glucagon-producing cells and restored the expression of α-amylase in E2F1/E2F2 DKO mice ( Figure 5 ). Histological and morphological abnormalities described in DKO pancreas such as loss of normal architecture, lower number of acini and increased number of ductal structures, were completely absent in E2F1/E2F2/p53 TKO mice (Figure 6a) . Furthermore, the acinar cell hypertrophy with marked karyomegaly characteristic of DKO pancreases was completely rescued in TKO animals ( Figure 6b ). Indeed, mean size of the nuclei in TKO pancreatic acinar cells was clearly reduced compared with the mean size of nuclei in DKO cells (3.17 ± 0.72-fold over WT in DKO mice versus 1.55 ± 0.24-fold over WT in TKO mice). Endocrine pancreas, which was atrophic in DKO mice, appeared overtly normal when p53 was eliminated (Figures 6  and 7a) . Importantly, glucose levels in serum of TKO mice were similar to the levels found in WTs (Figure 7c ), suggesting that insulin secreted by pancreas of E2F1/E2F2/p53 TKO mice is sufficient to maintain normoglycemia.
Histological as well as functional features of other organs that are severely affected in DKO mice, such as testicles and salivary glands, were also overtly normal in TKO mice, including their ability to generate offspring (Supplementary Figure 5 and data not shown). Taken together, these data indicate that p53 is the crucial mediator of the abnormal phenotype displayed by organs in mice lacking E2F1/E2F2. Disruption of p53 in E2F1/E2F2 mutant mice shortens lifespan owing to the emergence of thymic lymphomas. Unexpectedly, lifespan of TKO mice was found to be significantly shorter than that of WT or p53 − / − mice (Figure 8a ), even though TKO mice were normoglycemic and showed normal gland structure (Figures 6 and 7) . While performing the necropsies we noted that the thymus was severely hypertrophic in E2F1/E2F2/ p53 TKO mice. Relative thymus weight in TKO mice was 6-fold higher than that of WT or DKO mice (Figures 8b and c) , suggesting that the reduced survival rate of TKO animals stems from a respiratory failure due to thymic tumor growth, as demonstrated for p53 − / − mice. 25 Histological sections of TKO thymus confirmed the development of T-cell lymphoblastic leukemia/lymphoma in these mice (Figures 8d and e) . Taken together, these findings imply that depletion of E2F1/2 is not only unable to suppress tumor development, but rather increases the oncogenic potential in normal cells.
Discussion
Here we show that E2F1 and E2F2 are crucial players in an essential pathway involved in the maintenance of a post-mitotic state by limiting the capability of the DNA
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A Iglesias-Ara et al replication and cell cycle progression machinery. Failure of this control mechanism results in exacerbated CDK activity and inappropriate DNA replication that induces a DDR pathway and predisposes cells to tumorigenesis. Consequently, an apoptotic program that affects tissue integrity is activated.
In this work, we have analyzed the pathway that leads to apoptosis in pancreas lacking E2F1 and E2F2. It is known that apoptotic cell death in pancreas may be induced as consequence of diabetes, as aberrantly increased glucose levels trigger both extrinsic and intrinsic apoptotic pathways. 26 Conversely, apoptosis may also be the causal factor in mouse models of diabetes. [27] [28] [29] [30] In E2F1/E2F2-deficient cells, altered expression of proapoptotic mediators and mitochondrial membrane depolarization preceded the onset of diabetes, suggesting that apoptosis is a triggering event for pancreatic degeneration and diabetes in our mouse model. Furthermore, our results demonstrate that apoptosis in mice lacking E2F1/E2F2 is exclusively dependent on p53, since targeted inactivation of p53 hinders apoptosis and restores normal pancreas phenotype. Additionally, the fact that elimination of p21 CIP1 does not rescue the phenotype of DKO cells suggests that the program elicited by p53 in DKO mice is not primarily aimed to arrest cell cycle, but to activate apoptosis.
Our data strongly suggest that activation of p53 pathway in DKO cells is associated with their aberrant DNA replication. Accumulating experimental evidence indicates that p53 can be activated as part of the DDR pathway triggered by replicative stress. 31 Moreover, abnormal DNA replication leading to p53-dependent apoptosis and inner ear involution occurs after concomitant inactivation of p19 ARF and p21
CIP1
CDKis. 32 In line with these studies, our data showing that in vivo inhibition of DNA replication dose dependently prevents activation of the DDR and accumulation of p53 provide support for the notion that replication stress has a major causative role in p53 activation in cells lacking E2F1 and E2F2. DKO pancreas is overtly normal until the second week of postnatal age, 19 suggesting that E2F1 and E2F2 are dispensable for the timely cellular proliferation occurring up to this age in pancreas. During terminal differentiation, in contrast, they appear to have a major role as repressors of the cell cycle by promoting attenuation of DNA replication. Similar findings have been reported for differentiating monocyte and intestinal epithelial cells. 13, 17 However, the cell fates in these cases are different from those observed in pancreatic tissue, as monocyte progenitor cells lacking E2F1/2 result in senescence, and intestinal progenitor cells lacking E2F1-3 lead to p53-independent apoptosis. The mechanism that leads to replication stress in DKO cells is still unknown, and it would be interesting to determine whether it involves illegitimate replication origin firing and fork stalling, as shown for replication stress caused by overexpression of Cdt1 33 or by aberrant CDK activity 34 in some cell types. A controlled CDK activity is key to maintain genome integrity during S phase, 35 and it has been reported that most of the DNA replication stress arises as a result of elevated CDK activity. 36 Interestingly, this phenotype can be alleviated by nucleotide addition. 34, 37 In E2F1
− / − cells, overexpression of replication proteins such as Mcm3, Cdc6 and Orc1, together with the increased Cyclin/CDK activity, could be the source of the observed DNA damage. It remains, however, to be determined what the contributing role of CDK activity in unscheduled DNA replication is, and the role of intracellular nucleotide pools in DKO phenotype.
Many of the features exhibited by the E2F1/E2F2 mutant mouse model are similar to those exhibited by aging animals, including general tissue atrophy and degeneration. 38 Interestingly, animal models of progeria have also shown that the absence of p53 relieves some of the growth disadvantages of aging and enhances the lifespan of these animals, unless cancer arises. 39 Individuals with rare genetic diseases that accelerate aging, such as Werner or MDP (Mandibular hypoplasia, Deafness and Progeroid features) syndromes are also known to develop tissue degeneration that affects many organs including the pancreatic gland. Intriguingly, these two syndromes are the result of mutations in genes involved in DNA replication, WRN helicase and DNA polymerase δ catalytic subunit encoding gene POLD1, respectively, 40, 41 suggesting that DNA replication stress, such as that exhibited by E2F1/2-deficient cells, may drive tissue involution and aging in some pathological conditions. E2F1 and E2F2 represent controversial players in cell-cycle control, exhibiting dual behavior as tumor suppressors or as oncogenes. Excess of E2F1 may promote proliferation, but may also enhance apoptosis, and there are numerous examples in which deregulation of E2F1 can have both positive and negative effects on tumor growth. 42 Specifically, in pancreatic cancer cell lines, E2F1 is necessary for expression of cancer cell markers, such as Muc4. 43 Conversely, ectopic E2F1 expression in combination with chemotherapeutic drugs results in a strong induction of apoptosis in pancreatic cancer cells. 44 E2F2 has been studied to a lesser extent, but there is evidence of a similar duality of functions accomplished by this factor. 45, 46 This dual role of E2Fs seems to depend on the level of E2F activity, but also on the cell context background, greatly influenced by the presence or absence of pRb and/or p53. 6 Our results showing that depletion of E2F1/2 can generate apoptotic signals in cells but promote tumor development upon loss of p53 are consistent with this notion. Inactivation of p53 in E2F1-3-deficient fibroblasts has also been shown to result in transformation of this cell type, 47 implying a general role for the E2F-p53 axis in malignancy. Thus, exacerbating DNA replication rates either by inactivating pRb, 48 or, paradoxically, by depleting E2F1/2 could lead to atrophy in a p53-competent context, but be oncogenic in a p53-deficient context. These observations suggest that cells have more than one failsafe mechanism whereby deregulation of one arm of tumor suppression is not sufficient to initiate tumorigenesis, and instead leads to tissue atrophy. Our findings have implications in the cancer field, given the increasing interest in developing E2F inhibitors for the treatment of cancer. Several studies have shown the usefulness of this approach for inhibition of tumor cell growth. 49, 50 Our results indicate that depleting E2F activity in a context in which the pRb and the p53 pathways are functional, which is the situation of most non-cancerous cells in an organism, renders cells susceptible to become − / − and E2F1/E2F2/p53 TKO mice (n = 15/genotype) analyzed using a log-rank non-parametric test and expressed as Kaplan-Meier survival curves (E2F1/E2F2 DKO versus WT, Po0.0001; E2F1/E2F2/p53 TKO versus WT, Po0.0001; E2F1/E2F2/p53 TKO versus E2F1/E2F2 DKO, Po0.0001; E2F1/E2F2/p53 TKO versus p53 − / − , Po0.0001). (b) Thymus weight expressed as fraction of total body weight in 4-to 6-month-old animals (n = 5 per genotype, *Po0.0001). (c) Representative thymus organs obtained from of 6-month-old WT, E2F1/E2F2 DKO and E2F1/E2F2/p53 TKO animals. (d) Thymus sections obtained from 6-month-old WT and E2F1/E2F2/p53 TKO animals stained with hematoxylin/eosin (H/E, x40). Note that the typical structure of WT thymus divided into cortex and medulla is completely loss in TKO thymus. (e) Immunohistochemical analysis of thymus sections obtained from 6-month-old E2F1/E2F2/p53 TKO animals to detect CD3, CD20 and TDT (x40). Note that E2F1/E2F2/p53 TKO mice exhibit positive staining for CD3 and TDT and negative staining for CD20, implying that TKO mice develop T-cell lymphoblastic leukemia/lymphoma E2F-p53 regulatory axis in tissue homeostasis A Iglesias-Ara et al cancerous owing to an increased genomic instability. Thus, both transformed and non-transformed cells should be examined when developing therapeutic approaches targeting E2F for cancer treatment. E2F1/2-deficient mice could constitute a useful model in which to study the mechanisms regulating the control of malignant transformation as well as tissue degeneration in both normal and cancer cells. 
animals. All procedures were approved by the University of the Basque Country Animal Care and Use Committee.
Metabolic studies. Blood glucose levels were determined from blood taken from mouse tails, using an automatic glucose monitor. Blood for insulin levels was collected from the submandibular vein. Insulin levels were measured in serum by ELISA (ALPCO Diagnostics, Windham, NH, USA), according to the manufacturer's instructions. Amount of ROS in pancreas was determined in liquid nitrogen-frozen pancreases, using OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the protocol of the manufacturer.
Histology, immunohistochemistry and in vivo S-phase labeling. Freshly collected tissues were fixed with 10% formalin in PBS and embedded in paraffin for staining with hematoxilin and eosin.
Immunohistochemical assays were performed on tissues fixed with 4% paraformaldehyde in PBS using the indirect immunoperoxidase detection protocol EnvisionFLEX (DAKO A/S, Glostrup, Denmark) in the automatic system DAKO autostainer link 48 (DAKO). The antibodies used were rabbit mAbs to glucagon (1 : 300; DAKO), Terminal Deoxynucleotidyl Transferase (TDT) (1 : 50; DAKO), γ-H2AX (1 : 2000; Millipore, Billerica, MA, USA), and mouse mAbs to insulin (1 : 3,000), α-amylase (2 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA), CD3 (1 : 50; DAKO) and CD20 (1 : 400; DAKO). Control immunostainings using the secondary antibody in the absence of the primary antibody were routinely performed.
For S-phase labeling, mice were injected intraperitoneally (i.p.) with BrdU (Sigma) (50 μg/g of body weight). Mouse organs were harvested 8 h later, and fixed in 10% formalin. Tissue sections were processed for inmunohistochemistry using the rabbit monoclonal mAb to BrdU (1 : 100; DAKO). Images were captured using Olympus Cell B software (Digital Image Systems, Athens, Greece).
WTand DKO mice were injected i.p. with 5-120 μg/g aphidicolin (Sigma). Controls received an equivalent volume of normal saline i.p. After 30 min, mice were injected i. p. with BrdU. Mouse organs were harvested 4 h after the injection with aphidicolin. Freshly collected tissues were divided into two pieces and one set was fixed with 10% formalin in PBS and embedded in paraffin, whereas the other set was placed immediately in liquid nitrogen to perform protein extraction.
Immunofluorescence of pH3 was performed on frozen tissue sections. Slides were microwaved at boiling for 30 min in 10 mM citric acid buffer, pH 6.0 and allowed to cool (30 min) before 5 min washes in 50 mM TBS, 0.1% Tween-20 (pH 7.4). Tissue sections were immunostained using primary antibody against pH3 (Ser15; Upstate, Millipore) and Alexa Fluor 594 (Molecular Probes, Carlsbad, CA, USA) secondary antibody. DNA was counterstained with Hoechst 33288 dye and analysis was performed using an Olympus Fluoview FV500 microscope (Olympus America, Center Valley, PA, USA) and Olympus Fluoview 1.7b software (Olympus America).
Image J Software from NIH (National Institutes of Health, Bethesda, MD, USA) was used to determine the percentage of BrdU+, γ-H2AX+ or pH3+ nuclei in images of three randomly selected fields (×20 magnification) from 2 to 4 pancreases per genotype.
Pancreatic cell isolation. Individual pancreatic cells were prepared essentially as previously described. 54 Briefly, 2.5 ml of 0.3 mg/ml collagenase solution (Clostridium histolyticum; Roche, Nutley, NJ, USA) in KHB, pH 7.4 (118 mM NaC1, 25 mM NaHCO 3 , 4.7 mM KC1, 1.1 mM MgCl 2 ,, 2.5 mM CaCl 2 , 1.2 mM NaHPO 4 , and 14 mM glucose) was injected into the pancreas with a 27 gauge needle, and the gland was incubated at 37°C in a 15-ml polythene flask containing additional 2.5 ml of collagenase solution. After 20 min, the solution was replaced with KHB lacking Mg 2+ and Ca 2+ and containing 2 mM EDTA and incubated for 3 min. The solution was then replaced with fresh calcium-free KHB and the tissue was incubated for a further 3 min. This was followed by a final incubation in collagenase in calcium-containing KHB for 20-30 min, until mostly single cells were present. The tissue was then further dispersed and filtered through a 100-μm nylon mesh (Spectrum Laboratories, Rancho Dominguez, CA, USA).
Analysis of mitochondrial membrane potential, mitochondrial mass and apoptosis. Mitochondrial membrane potential was measured using the lipophilic cationic probe JC-1 as described. 55 JC-1 dye was purchased from Molecular Probes (Leiden, The Netherlands) and stored in DMSO (Sigma). Cells were adjusted to a density of 1 × 10 6 /ml and stained with 3 μM JC-1 for 15 min at 37 ºC. The mitochondrial uncoupler carbonyl cyanide m-chloro phenyl hydrazone (CCCP, Molecular Probes) was used at 50 μM for 5 min previous to incubation with JC-1 dye as a control to measure compromised mitochondrial membrane potential. Cells were then washed twice with pre-warmed KHB buffer and resuspended in KHB. Fluorescence was detected and analyzed using a FACSCalibur flow cytometer (Becton & Dickinson, San Jose, CA, USA).
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